More Talent Rushes To The Synthetic Biology Gold Mine: Venture Capitalist Mitchell Mutz Leaves Roche To Join Codon Capital Synthetic biology sells picks and shovels for the $4 trillion bioeconomy, and Codon Capital sees this opportunity. Mitchell Mutz—the accomplished venture investor, biotech serial entrepreneur, and inventor—joins Codon Capital to build a better world with biology.